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ABSTRACTS
Gregory L. Moneta, MD, Abstracts Section Editor
Renal dysfunction and prolonged visceral ischemia increase mortality
rate after suprarenal aneurysm repair
Picknell CD, Cowan AR, Kerle MI, et al. Br J Surg 2003;90:1142-6.
Conclusion: In-hospital mortality was 4.5% for juxtrarenal aortic an-
eurysm (JAA) repair and 20% for type IV thoracoabdominal aneurysm
(TAA) repair. Preoperative renal dysfunction correlates with mortality after
type IV TAA repair.
Summary: This article compares results of JAA and type IV TAA
repair. Data were collected prospectively from 1993 to 2000. One hundred
thirty patients underwent type IV TAA repair, and 44 patients underwent
JAA repair. Perioperative risk factors, operative details, and mortality rates
were compared. Factors that influenced mortality for type IV TAA repair
were determined.
Technique for repair of JAA entailed an aortic clamp above the renal
arteries, either suprarenal or supraceliac, with the majority suprarenal, and
the proximal graft anastomosis below the renal arteries. With type IV TAA
repairs, a supraceliac clamp was used. The proximal anastomosis was con-
structed with an oblique aortic incision, with the anastomosis extending up
to or above the level of the celiac axis, with separate reimplantation of the left
renal artery. Bypass of the left side of the heart and selective visceral artery
perfusion were not used.
There were 2 in-hospital deaths in patients undergoing JAA repair
(4.5%) and 26 in patients undergoing type IV TAA repair (20.0%; P .016.
Median blood loss for JAA repair was 3.2 L (range, 0.8-14.5 L), and for type
IV TAA repair was 3.7 L (range, 0.7-26.0 L). Mean intraoperative number
of blood transfusions in the JAA group was 8 units (range, 1-29 units), and
in the TAA group was 9 units (range, 1-55 units). Elevated serum creatinine
concentration was the only preoperative factor (P  .013), and visceral
ischemia the only operative factor (P .001) that correlated with death after
TAA repair.
Comment: Results for repair of JAA are what one would expect from a
tertiary care center. Mortality for repair of type IV TAA is higher than in
some previous reports, and may reflect that 25% of the type IV TAA repairs
were considered “urgent,” although no type IV TAAs were ruptured. The
data indicate that the mortality rate for JAA repair differs little from that for
standard infrarenal AAA repair. However, type IV TAA repair has higher
mortality, with perioperative renal dysfunction a marker for increased risk for
TAA repair, a finding consistent with previous studies. Renal dysfunction is
a strong relative contraindication to type IV TAA repair.
Protective carotid stenting: Clinical advantages and complications of
embolic protection devices in 424 consecutive patients
Cremonesi A, Manetti R, Setacci F, et al. Stroke 2003;34:1936-43.
Conclusions: In a series of 442 patients undergoing carotid angio-
plasty or stenting the overall neurologic complication rate was 2.5%, and
complications related to the cerebral protection device occurred in 4 of 442
patients (0.9%).
Summary: The authors studied complications related to cerebral pro-
tection devices during angioplasty or stenting of the extracranial carotid
artery in 442 patients who underwent percutaneous angioplasty or stenting
of the extracranial carotid artery. Fifty-seven percent of the patients had no
symptoms. Six different cerebral protection devices were used during this
study. The three most commonly used devices were the Johnson & Johnson-
Cordis Angioguard Filter (37.8%), the Boston Scientific FilterWire EX
(25.1%), and the EV3 Microvena Trap Filter (18.9%).
The procedure was successfully performed in 440 of 442 patients, with
no periprocedural deaths. In 342 patients stents were placed. Three hundred
thirty-nine of the stents were self-expanding. Predilation was performed
with coronary balloons in 167 patients. The in-hospital stroke and death rate
and 30-day ipsilateral stroke and death rate was 1.1%. Neurologic compli-
cations included four intracranial hemorrhages, one major stroke, four
minor strokes, four transient ischemic attacks, and six instances of transient
neurologic symptoms resulting from intolerance of occlusive protection
devices, for a total neurologic complication rate of 2.5%. The overall
procedure-related complication rate was 3.4%. There were four cerebral
protection device–related complications, including one carotid dissection
resulting in occlusion, one trapped guide wire requiring operative removal,
and two instances of limited dissection. In the retrieved protection devices,
69% demonstrated visible plaque debris captured by the device.
Comment: The data add to the growing trend of routine use of
protection devices for carotid artery stenting. In an editorial accompanying
this article, Drs Eckert and Zeumer, from Hamburg, Germany, note that the
use of cerebral protection devices has occurred in conjunction with increased
operator experience and improvements in guide wires, stents, and peripro-
cedural anticoagulation regimens. While cerebral protection devices may
contribute to improved results with carotid artery angioplasty or stenting,
other facets of the procedure are also evolving and being improved.
Relation of levels of hemostatic factors and inflammatory markers to
ankle-brachial index
McDermott M, Green D, Greenland P, et al. Am J Cardiol 2003; 92:194-9
Conclusion: D-Dimer levels may be the most sensitive inflammatory or
hemostatic marker in providing a serologic indication of the extent of lower
extremity atherosclerosis.
Summary: Some components of the hemostatic system, including
tissue plasminogen activator, plasminogen activator inhibitor, and pro-
thrombin 1.2, as well as D-dimer, are increased in patients with lower
extremity peripheral arterial disease (PAD) compared with patients without
PAD. Inflammatory markers such as C-reactive protein, fibrinogen, and
serum amyloid A have been less consistently associated with PAD.
The authors correlated levels of these hemostatic and inflammatory
markers with ankle-brachial index (ABI) in 370 subjects with an ABI less
than 0.9 and 231 subjects with an ABI of 0.9 to 1.50. In patients without a
history of cardiac or cerebrovascular disease the ABI, in an unadjusted
analysis, was inversely associated with log D-dimer (P .001), log C-reactive
protein (P  .001), log prothrombin 1.2 (P  .001), and log fibrinogen
(P  .005). At multivariable regression analysis, CRP was associated inde-
pendently with ABI only in patients with a history of cardiac or cerebrovas-
cular disease and not in patients without a history of cardiac or cerebrovas-
cular disease. D-Dimer, however, was associated independently with ABI in
patients with a history of cardiac or cerebrovascular disease and also in
patients without a history of cardiac or cerebrovascular disease.
Comment: The results demonstrate that D-dimer levels are associated
with the extent of lower extremity PAD as measured by ABI. The data
suggest that patients with more severe PAD, as reflected by ABI, have
ongoing fibrinolysis and thrombosis that is reflected in higher D-dimer levels.
Altered patterns of gene expression distinguishing ascending aortic
aneurysms from abdominal aortic aneurysms: Complementary DNA
expression profiling in molecular characterization of aortic disease
Absei TS, Sundt TM III, Tung WS, et al. J Thorac Cardiovasc Surg
2003;126:344-57.
Conclusion: Thoracic aortic aneurysms (TAAs) and abdominal aortic
aneurysms (AAAs) are characterized by significant molecular heterogeneity,
suggesting different pathophysiologic mechanisms of aortic and thoracic
aneurysm disease.
Summary: The authors compared patterns of gene expression in
normal thoracic and abdominal aortas and in TAAs and AAAs. Aortic tissue
was obtained during surgical repair of TAAs and infrarenal AAAs (n  4
each). Normal thoracic and abdominal aortic control tissue was obtained
from organ donors. Radiolabeled complementary DNA (cDNA) was pre-
pared for each specimen. This was hybridized to cDNA microarrays, and
levels of gene expression were determined for each site.
There were 1185 genes examined, with 112 genes differentially ex-
pressed between normal thoracic aorta and TAAs (P  0.05). In a compar-
ison of infrarenal AAAs and normal abdominal aortas, 104 genes were
differentially expressed. Quantitative increases in gene expression unique for
TAAs occurred for 97 genes. Quantitative increases in gene expression that
were unique for infrarenal AAAs occurred for 61 genes. Only four direction-
ally concordant alterations in gene products occurred in both TAAs and
infrarenal AAAs: matrix metalloproteinase 9/gelatinase b, V-yes-1 onco-
gene, mitogen-activated protein kinase 9, and intracellular adhesion mole-
cule 1/cd 54.
Comment: The authors examined end-stage aneurysm tissue and
compared it with normal control tissue. Differences in genetic expression
delineated in this study may reflect age differences, changes resulting from
aneurysm degeneration, and other factors that differ between patients and
control subjects. It cannot be determined whether differential gene expres-
sions represent cause or effect.
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